SPDR S&P Biotech (XBI) 67.77 $XBI Biotech ETFs
Post# of 273249
Posted On: 09/26/2016 7:11:46 PM
SPDR S&P Biotech (XBI) 67.77 $XBI
Biotech ETFs in Focus on Tobira Therapeutics' Massive Gain
Sanghamitra Saha - Zacks Investment Research - Wed Sep 21, 10:23AM CDT
Tobira Therapeutics surged following the news that Allergan is buying it at an astounding premium and drove several biotech ETFs higher.
BBP: 33.97 (-0.41), AGN: 238.68 (-5.26), SBIO: 26.78 (-0.53), BBC: 22.89 (-0.16), GLMD: 5.30 (+0.08), XBI: 67.77 (-0.37), CNAT: 2.10 (-0.01), ICPT: 166.02 (-0.21), IBB: 294.53 (-3.65)
You Can’t Ignore the Biotech Breakout
Greg Guenthner - Daily Reckoning - Tue Sep 20, 8:46AM CDT
This post You Can’t Ignore the Biotech Breakout appeared first on Daily Reckoning . The major averages couldn’t hold onto their morning gains yesterday. Stocks spent the day slowly sinking into the red. But that didn’t stop a surprise FDA...
XBI: 67.77 (-0.37), SRPT: 59.66 (+1.83), PTCT: 11.64 (-0.02)
Biotechnology ETFs Rally on Sarepta FDA Drug Approval
editor@etftrends.com (ETF Trends) - ETF Trends - Mon Sep 19, 3:09PM CDT
Sarepta Therapeutics (NasdaqGS: SRPT) surged Monday and lifted biotechnology-related exchange traded funds after the Food and Drug Administration approved the Duchenne muscular dystrophy drug eteplirsen. Leading the charge in the ETF space on Monday,...
BBC: 22.89 (-0.16), XBI: 67.77 (-0.37), PTH: 53.39 (-0.22), IBB: 294.53 (-3.65)
SPDR S&P Biotech ETF Rises 2.72% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Sep 19, 11:55AM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $64.53 to a high of $67.48. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high of $65.10 on volume of 5.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XBI: 67.77 (-0.37)
Inside the Recent Surge in Biotech ETFs
Sanghamitra Saha - Zacks Investment Research - Wed Sep 14, 1:19PM CDT
What caused biotech ETFs to tack on solid gains on September 12.
PBE: 42.69 (-0.68), SBIO: 26.78 (-0.53), PRGO: 95.73 (-1.67), RPTP: 8.96 (-0.04), GILD: 80.62 (-0.75), FBT: 100.98 (-0.90), XBI: 67.77 (-0.37), FOMX: 9.83 (-0.37), HZNP: 18.82 (-0.61), IBB: 294.53 (-3.65)
SmarTrend Watching for Potential Pullback in Shares of SPDR S&P Biotech ETF After 2.13% Gain
Comtex SmarTrend(R) - Wed Sep 14, 12:14PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $62.65 to a high of $64.54. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $63.46 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XBI: 67.77 (-0.37)
Watch for SPDR S&P Biotech ETF to Potentially Pullback After Gaining 2.88% Yesterday
Comtex SmarTrend(R) - Tue Sep 06, 2:46PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $60.68 to a high of $61.99. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $60.94 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XBI: 67.77 (-0.37)
Biotech ETF Industry Outlook
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 2:39PM CDT
It has been a challenging environment for the biotech industry so far; how are these ETFs expected to perform for the rest of 2016.
PBE: 42.69 (-0.68), FBT: 100.98 (-0.90), XBI: 67.77 (-0.37), BBH: 117.02 (-1.55), IBB: 294.53 (-3.65)
After Yesterday's Decline of 1.56%, SPDR S&P Biotech ETF Offers Investors Better Value
Comtex SmarTrend(R) - Wed Aug 31, 12:25PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $59.79 to a high of $60.94. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $60.17 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XBI: 67.77 (-0.37)
Healthcare ETFs Need Some Rest
editor@etftrends.com (ETF Trends) - ETF Trends - Wed Aug 31, 9:48AM CDT
It has not been a typical year for healthcare exchange traded funds such as the Vanguard Health Care ETF (NYSEArca: VHT) and the Health Care Select Sector SPDR (NYSEArca: XLV). Political posturing has been weighing on the S&P 500’s...
XBI: 67.77 (-0.37), IBB: 294.53 (-3.65), VHT: 133.21 (-1.55), XLV: 72.26 (-0.85)
10 Most Read ETF Articles of the Week (August 22-26)
editor@etftrends.com (ETF Trends) - ETF Trends - Fri Aug 26, 5:42PM CDT
Each day, ETFtrends.com publishes news, strategy and commentary on ETFs in the realms of Commodities, Currency, Equities and Smart-Beta to name a few. Here’s a look at the 10 most read articles of the week on ETF Trends, Aug. 22-26, 2016. Click the...
HYG: 86.38 (-0.38), USO: 10.43 (+0.24), GDXS: 15.55 (+0.25), GDJS: 1.90 (-0.10), XBI: 67.77 (-0.37), BNO: 13.85 (+0.29), IBB: 294.53 (-3.65), ZBIO: 20.22 (+0.71), XLV: 72.26 (-0.85), JNK: 36.35 (-0.16), BIS: 30.54 (+0.72), DUST: 32.67 (+0.83), XLF: 19.07 (-0.31), GDX: 26.78 (-0.24), LABD: 16.28 (+0.21), VHT: 133.21 (-1.55), JDST: 23.39 (+0.77)
Biotech ETFs in Focus After Mylan's EpiPen Controversy
Sanghamitra Saha - Zacks Investment Research - Fri Aug 26, 9:27AM CDT
Mylan offers discounts to the purchase of EpiPen to cool down criticism over its steep price. How will biotech ETFs take this move?
GNRX: 24.86 (-0.43), XBI: 67.77 (-0.37), MYL: 41.18 (-0.88), IBB: 294.53 (-3.65)
Pfizer Acquires Medivation, Renews Biotech M&A Bets
editor@etftrends.com (ETF Trends) - ETF Trends - Mon Aug 22, 1:20PM CDT
Pfizer (NYSE: PFE) announced a $14 billion deal to acquire cancer drug developer Medivation (NasdaqGS: MDVN), propelling the broader biotechnology exchange traded funds higher on speculation of more deals in the sector. Biopharmaceutical giant Pfizer...
PBE: 42.69 (-0.68), SBIO: 26.78 (-0.53), BBC: 22.89 (-0.16), XBI: 67.77 (-0.37)
Another Endorsement for Biotech ETFs
editor@etftrends.com (ETF Trends) - ETF Trends - Tue Aug 16, 10:30AM CDT
The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), which tracks the Nasdaq Biotechnology Index, and rival biotechnology exchange traded funds, seem to have put the woes experienced earlier this year behind them and recently have been in rally...
FBT: 100.98 (-0.90), XBI: 67.77 (-0.37), IBB: 294.53 (-3.65)
After Yesterday's Rally of 1.73% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 15, 12:42PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $62.72 to a high of $63.61. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $62.77 on volume of 2.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XBI: 67.77 (-0.37)
SmarTrend Watching for Potential Rebound in Shares of SPDR S&P Biotech ETF After 2.50% Loss
Comtex SmarTrend(R) - Wed Aug 10, 12:10PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $60.93 to a high of $62.77. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $62.39 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XBI: 67.77 (-0.37)
Biotech ETFs in Focus on Tobira Therapeutics' Massive Gain
Sanghamitra Saha - Zacks Investment Research - Wed Sep 21, 10:23AM CDT
Tobira Therapeutics surged following the news that Allergan is buying it at an astounding premium and drove several biotech ETFs higher.
BBP: 33.97 (-0.41), AGN: 238.68 (-5.26), SBIO: 26.78 (-0.53), BBC: 22.89 (-0.16), GLMD: 5.30 (+0.08), XBI: 67.77 (-0.37), CNAT: 2.10 (-0.01), ICPT: 166.02 (-0.21), IBB: 294.53 (-3.65)
You Can’t Ignore the Biotech Breakout
Greg Guenthner - Daily Reckoning - Tue Sep 20, 8:46AM CDT
This post You Can’t Ignore the Biotech Breakout appeared first on Daily Reckoning . The major averages couldn’t hold onto their morning gains yesterday. Stocks spent the day slowly sinking into the red. But that didn’t stop a surprise FDA...
XBI: 67.77 (-0.37), SRPT: 59.66 (+1.83), PTCT: 11.64 (-0.02)
Biotechnology ETFs Rally on Sarepta FDA Drug Approval
editor@etftrends.com (ETF Trends) - ETF Trends - Mon Sep 19, 3:09PM CDT
Sarepta Therapeutics (NasdaqGS: SRPT) surged Monday and lifted biotechnology-related exchange traded funds after the Food and Drug Administration approved the Duchenne muscular dystrophy drug eteplirsen. Leading the charge in the ETF space on Monday,...
BBC: 22.89 (-0.16), XBI: 67.77 (-0.37), PTH: 53.39 (-0.22), IBB: 294.53 (-3.65)
SPDR S&P Biotech ETF Rises 2.72% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Sep 19, 11:55AM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $64.53 to a high of $67.48. Yesterday, the shares gained 2.7%, which took the trading range above the 3-day high of $65.10 on volume of 5.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XBI: 67.77 (-0.37)
Inside the Recent Surge in Biotech ETFs
Sanghamitra Saha - Zacks Investment Research - Wed Sep 14, 1:19PM CDT
What caused biotech ETFs to tack on solid gains on September 12.
PBE: 42.69 (-0.68), SBIO: 26.78 (-0.53), PRGO: 95.73 (-1.67), RPTP: 8.96 (-0.04), GILD: 80.62 (-0.75), FBT: 100.98 (-0.90), XBI: 67.77 (-0.37), FOMX: 9.83 (-0.37), HZNP: 18.82 (-0.61), IBB: 294.53 (-3.65)
SmarTrend Watching for Potential Pullback in Shares of SPDR S&P Biotech ETF After 2.13% Gain
Comtex SmarTrend(R) - Wed Sep 14, 12:14PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $62.65 to a high of $64.54. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $63.46 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XBI: 67.77 (-0.37)
Watch for SPDR S&P Biotech ETF to Potentially Pullback After Gaining 2.88% Yesterday
Comtex SmarTrend(R) - Tue Sep 06, 2:46PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $60.68 to a high of $61.99. Yesterday, the shares gained 2.9%, which took the trading range above the 3-day high of $60.94 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XBI: 67.77 (-0.37)
Biotech ETF Industry Outlook
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 2:39PM CDT
It has been a challenging environment for the biotech industry so far; how are these ETFs expected to perform for the rest of 2016.
PBE: 42.69 (-0.68), FBT: 100.98 (-0.90), XBI: 67.77 (-0.37), BBH: 117.02 (-1.55), IBB: 294.53 (-3.65)
After Yesterday's Decline of 1.56%, SPDR S&P Biotech ETF Offers Investors Better Value
Comtex SmarTrend(R) - Wed Aug 31, 12:25PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $59.79 to a high of $60.94. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $60.17 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XBI: 67.77 (-0.37)
Healthcare ETFs Need Some Rest
editor@etftrends.com (ETF Trends) - ETF Trends - Wed Aug 31, 9:48AM CDT
It has not been a typical year for healthcare exchange traded funds such as the Vanguard Health Care ETF (NYSEArca: VHT) and the Health Care Select Sector SPDR (NYSEArca: XLV). Political posturing has been weighing on the S&P 500’s...
XBI: 67.77 (-0.37), IBB: 294.53 (-3.65), VHT: 133.21 (-1.55), XLV: 72.26 (-0.85)
10 Most Read ETF Articles of the Week (August 22-26)
editor@etftrends.com (ETF Trends) - ETF Trends - Fri Aug 26, 5:42PM CDT
Each day, ETFtrends.com publishes news, strategy and commentary on ETFs in the realms of Commodities, Currency, Equities and Smart-Beta to name a few. Here’s a look at the 10 most read articles of the week on ETF Trends, Aug. 22-26, 2016. Click the...
HYG: 86.38 (-0.38), USO: 10.43 (+0.24), GDXS: 15.55 (+0.25), GDJS: 1.90 (-0.10), XBI: 67.77 (-0.37), BNO: 13.85 (+0.29), IBB: 294.53 (-3.65), ZBIO: 20.22 (+0.71), XLV: 72.26 (-0.85), JNK: 36.35 (-0.16), BIS: 30.54 (+0.72), DUST: 32.67 (+0.83), XLF: 19.07 (-0.31), GDX: 26.78 (-0.24), LABD: 16.28 (+0.21), VHT: 133.21 (-1.55), JDST: 23.39 (+0.77)
Biotech ETFs in Focus After Mylan's EpiPen Controversy
Sanghamitra Saha - Zacks Investment Research - Fri Aug 26, 9:27AM CDT
Mylan offers discounts to the purchase of EpiPen to cool down criticism over its steep price. How will biotech ETFs take this move?
GNRX: 24.86 (-0.43), XBI: 67.77 (-0.37), MYL: 41.18 (-0.88), IBB: 294.53 (-3.65)
Pfizer Acquires Medivation, Renews Biotech M&A Bets
editor@etftrends.com (ETF Trends) - ETF Trends - Mon Aug 22, 1:20PM CDT
Pfizer (NYSE: PFE) announced a $14 billion deal to acquire cancer drug developer Medivation (NasdaqGS: MDVN), propelling the broader biotechnology exchange traded funds higher on speculation of more deals in the sector. Biopharmaceutical giant Pfizer...
PBE: 42.69 (-0.68), SBIO: 26.78 (-0.53), BBC: 22.89 (-0.16), XBI: 67.77 (-0.37)
Another Endorsement for Biotech ETFs
editor@etftrends.com (ETF Trends) - ETF Trends - Tue Aug 16, 10:30AM CDT
The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), which tracks the Nasdaq Biotechnology Index, and rival biotechnology exchange traded funds, seem to have put the woes experienced earlier this year behind them and recently have been in rally...
FBT: 100.98 (-0.90), XBI: 67.77 (-0.37), IBB: 294.53 (-3.65)
After Yesterday's Rally of 1.73% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 15, 12:42PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $62.72 to a high of $63.61. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $62.77 on volume of 2.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
XBI: 67.77 (-0.37)
SmarTrend Watching for Potential Rebound in Shares of SPDR S&P Biotech ETF After 2.50% Loss
Comtex SmarTrend(R) - Wed Aug 10, 12:10PM CDT
SPDR S&P Biotech ETF (AMEX:XBI) traded in a range yesterday that spanned from a low of $60.93 to a high of $62.77. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $62.39 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
XBI: 67.77 (-0.37)
(0)
(0)Scroll down for more posts ▼